Literature DB >> 18195688

Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation.

R M Sobecks1, E J Ball, M Askar, K S Theil, L A Rybicki, D Thomas, S Brown, M Kalaycio, S Andresen, B Pohlman, R Dean, J Sweetenham, R Macklis, L Bernhard, K Cherni, E Copelan, J P Maciejewski, B J Bolwell.   

Abstract

Achievement of complete donor chimerism (CDC) after allogeneic nonmyeloablative hematopoietic stem cell transplantation (NMHSCT) is important for preventing graft rejection and for generating a graft-vs-malignancy effect. The alloreactivity of NK cells and some T-cell subsets is mediated through the interaction of their killer immunoglobulin-like receptors (KIRs) with target cell HLA/KIR ligands. The influence of KIR matching on the achievement of T-cell CDC after NMHSCT has not been previously described. We analyzed 31 patients undergoing T-cell replete related donor NMHSCT following fludarabine and 200 cGy TBI. Recipient inhibitory KIR genotype and donor HLA/KIR ligand matches were used to generate an inhibitory KIR score from 1 to 4 based upon the potential number of recipient inhibitory KIRs that could be engaged with donor HLA/KIR ligands. Patients with a score of 1 were less likely to achieve T-cell CDC (P=0.016) and more likely to develop graft rejection (P=0.011) than those with scores greater than 1. Thus, patients with lower inhibitory KIR scores may have more active anti-donor immune effector cells that may reduce donor chimerism. Conversely, patients with greater inhibitory KIR scores may have less active NK cell and T-cell populations, which may make them more likely to achieve CDC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195688     DOI: 10.1038/sj.bmt.1705954

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  The requirement for NKG2D in NK cell-mediated rejection of parental bone marrow grafts is determined by MHC class I expressed by the graft recipient.

Authors:  Joshua N Beilke; Jonathan Benjamin; Lewis L Lanier
Journal:  Blood       Date:  2010-08-24       Impact factor: 22.113

2.  Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.

Authors:  Amir A Toor; Roy T Sabo; Harold M Chung; Catherine Roberts; Rose H Manjili; Shiyu Song; David C Williams; Wendy Edmiston; Mandy L Gatesman; Richard W Edwards; Andrea Ferreira-Gonzalez; William B Clark; Michael C Neale; John M McCarty; Masoud H Manjili
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

3.  Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation.

Authors:  M Tavadze; L Rybicki; S Mossad; R Avery; M Yurch; B Pohlman; H Duong; R Dean; B Hill; S Andresen; R Hanna; N Majhail; E Copelan; B Bolwell; M Kalaycio; R Sobecks
Journal:  Bone Marrow Transplant       Date:  2014-08-11       Impact factor: 5.483

4.  Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.

Authors:  Ronald M Sobecks; Tao Wang; Medhat Askar; Meighan M Gallagher; Michael Haagenson; Stephen Spellman; Marcelo Fernandez-Vina; Karl-Johan Malmberg; Carlheinz Müller; Minoo Battiwalla; James Gajewski; Michael R Verneris; Olle Ringdén; Susana Marino; Stella Davies; Jason Dehn; Martin Bornhäuser; Yoshihiro Inamoto; Ann Woolfrey; Peter Shaw; Marilyn Pollack; Daniel Weisdorf; Jeffrey Milller; Carolyn Hurley; Stephanie J Lee; Katharine Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-08       Impact factor: 5.742

Review 5.  Biology and clinical effects of natural killer cells in allogeneic transplantation.

Authors:  Jonathan E Benjamin; Saar Gill; Robert S Negrin
Journal:  Curr Opin Oncol       Date:  2010-03       Impact factor: 3.645

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.